JPH10502073A - ブロメラインの医療への使用 - Google Patents

ブロメラインの医療への使用

Info

Publication number
JPH10502073A
JPH10502073A JP8502932A JP50293296A JPH10502073A JP H10502073 A JPH10502073 A JP H10502073A JP 8502932 A JP8502932 A JP 8502932A JP 50293296 A JP50293296 A JP 50293296A JP H10502073 A JPH10502073 A JP H10502073A
Authority
JP
Japan
Prior art keywords
bromelain
cells
preparation
cell
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8502932A
Other languages
English (en)
Japanese (ja)
Inventor
マイノット，トレーシー，リーハン
エングワーダ，クリスチャン
Original Assignee
コーテックス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーテックス リミテッド filed Critical コーテックス リミテッド
Publication of JPH10502073A publication Critical patent/JPH10502073A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP8502932A 1994-06-24 1995-06-26 ブロメラインの医療への使用 Pending JPH10502073A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9412711.5 1994-06-24
GB9412711A GB9412711D0 (en) 1994-06-24 1994-06-24 Medical use of bromelain
PCT/GB1995/001501 WO1996000082A1 (en) 1994-06-24 1995-06-26 Medical use of bromelain

Publications (1)

Publication Number Publication Date
JPH10502073A true JPH10502073A (ja) 1998-02-24

Family

ID=10757263

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8502932A Pending JPH10502073A (ja) 1994-06-24 1995-06-26 ブロメラインの医療への使用

Country Status (13)

Country Link
EP (1) EP0766565A1 (fi)
JP (1) JPH10502073A (fi)
KR (1) KR970703784A (fi)
CN (1) CN1151119A (fi)
AU (1) AU2749395A (fi)
CA (1) CA2193654A1 (fi)
FI (1) FI965204A (fi)
GB (1) GB9412711D0 (fi)
IL (1) IL114331A0 (fi)
NO (1) NO965564L (fi)
TW (1) TW403654B (fi)
WO (1) WO1996000082A1 (fi)
ZA (1) ZA955292B (fi)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533948A (ja) * 2014-11-13 2017-11-16 マイ，ジェニファー 癌の治療のための新規組成物

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526691D0 (en) * 1995-12-29 1996-02-28 Cortecs Ltd Medical use of proteases
US20020102253A1 (en) * 1997-02-25 2002-08-01 Mynott Tracey Lehanne Component of bromelain
WO1998038320A1 (en) * 1997-02-25 1998-09-03 Cortecs (Uk) Limited Component of bromelain
ES2403433T3 (es) * 1997-02-25 2013-05-17 Sarantis Pty Ltd Componente de bromelina
NO304766B1 (no) 1997-06-16 1999-02-08 Sintef Fingeravtrykksensor
DE19726244C2 (de) * 1997-06-20 2000-03-02 Mucos Pharma Gmbh & Co Verwendung proteolytischer Enzyme und Rutosid zur Vorbeugung bzw. Behandlung der Transplantatabstoßung
DE19726255C2 (de) * 1997-06-20 2000-03-16 Mucos Pharma Gmbh & Co Beeinflussung von Cytokinen durch proteolytische Enzyme und Rutosid
DE19726254C2 (de) * 1997-06-20 1999-10-21 Mucos Pharma Gmbh & Co Toleranzinduktion durch Proteasen
GB9713667D0 (en) * 1997-06-27 1997-09-03 Cortecs Ltd Enhancement of intestinal permeability
GB9819137D0 (en) * 1998-09-02 1998-10-28 Cortecs Uk Ltd Component of bromelain
GB9819138D0 (en) * 1998-09-02 1998-10-28 Cortecs Uk Ltd Nucleic acids and proteins from pineapple stem
DE19847114A1 (de) * 1998-10-13 2000-04-20 Mucos Pharma Gmbh & Co Beeinflussung von hyperaktiven T-Zellen durch proteolytische Enzyme
WO2000035436A2 (en) * 1998-12-16 2000-06-22 Warner-Lambert Company Treatment of arthritis with mek inhibitors
DE19957318A1 (de) * 1999-11-29 2001-06-21 Mucos Pharma Gmbh & Co Beeinflussung von TGF-Beta durch Proteolytische Enzyme
DE10018980A1 (de) * 2000-04-17 2001-11-08 Mucos Pharma Gmbh & Co Prophylaxe und Therapie von Diabetes mellitus I mit Hilfe proteolytischer Enzyme
EP1208849B1 (en) 2000-11-28 2015-10-28 URSAPHARM Arzneimittel GmbH Use of bromelain for adjuvant therapy during wound healing process
TW201419131A (zh) 2012-11-09 2014-05-16 Health & Life Co Ltd 具語音輔助之生物感測裝置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59225122A (ja) * 1983-05-23 1984-12-18 Kaken Pharmaceut Co Ltd 悪液質治療改善剤
ATE119780T1 (de) * 1989-10-06 1995-04-15 Mucos Emulsions Gmbh Katabolische enzyme zur induktion des tumornekrose-faktors (tnf).
DE4302060A1 (de) * 1993-01-26 1994-07-28 Mucos Pharma Gmbh & Co Verwendung von Bromelain zur Krebstherapie und/oder Metastasen-Prophylaxe
GB9313188D0 (en) * 1993-06-25 1993-08-11 Cortecs Ltd Medical use of enzymes

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017533948A (ja) * 2014-11-13 2017-11-16 マイ，ジェニファー 癌の治療のための新規組成物

Also Published As

Publication number Publication date
KR970703784A (ko) 1997-08-09
CA2193654A1 (en) 1996-01-04
WO1996000082A1 (en) 1996-01-04
FI965204A (fi) 1997-02-21
NO965564L (no) 1997-02-24
IL114331A0 (en) 1995-10-31
AU2749395A (en) 1996-01-19
EP0766565A1 (en) 1997-04-09
NO965564D0 (no) 1996-12-23
ZA955292B (en) 1997-07-28
CN1151119A (zh) 1997-06-04
GB9412711D0 (en) 1994-08-17
TW403654B (en) 2000-09-01
FI965204A0 (fi) 1996-12-23

Similar Documents

Publication Publication Date Title
JPH10502073A (ja) ブロメラインの医療への使用
US20120058133A1 (en) Inhibition of trna synthetases and therapeutic applications thereof
US9314485B2 (en) Use of PI3K M-TOR and AKT inhibitors to induce FOXP3 expression and generate regulatory T cells
Fernandez‐Martin et al. Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis
Mejri et al. Intraperitoneal murine Echinococcus multilocularis infection induces differentiation of TGF‐β‐expressing DCs that remain immature
CN105073110B (zh) 通过诱导分化成调节性t细胞和促进调节性t细胞增殖来抑制免疫应答的药物组合物
Reinhard et al. c‐Rel promotes type 1 and type 17 immune responses during Leishmania major infection
JP2010143945A (ja) ブロメライン成分を含む製薬組成物及び同ブロメライン成分を薬剤の調製に使用する方法
JP2022527338A (ja) 多能性幹細胞の胸腺上皮細胞および胸腺上皮前駆細胞分化を促進する方法
AU2003250892A1 (en) Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors
US9663777B2 (en) Component of bromelain
JP2000502697A (ja) プロテアーゼの医療への使用
US20100297123A1 (en) Combination therapy to inhibit t cell effector function
MXPA97000209A (en) Medical use of bromela
US20090142319A1 (en) METHOD TO EXPAND nTREG CELLS USING PI-3K ANTAGONIST
US20070184046A1 (en) Use of a phospholipase A2 for the preparation of pharmaceutical and/or cosmetic compositions for the local and/or systematic treatment and/or prevention of diseases and/or processes caused by intra- and extracellular pathogens expressing membrane phospholipids
US20110039791A1 (en) Acetylcholinesterase (ache)-derived peptide as an inducer of granulocytopoiesis, uses and methods thereof
WO2000014254A2 (en) Component of bromelain
Gaddis Cellular mechanisms involved in host responses to Porphyromonas gingivalis and its virulence factor Hemagglutinin B
Alic Involvement of proteases and kinases in mast cell activation
Schneider Unraveling The Paradoxical Impacts Of Toxoplasma Gondii On Dendritic Cell Stat1 Signaling
Evans III Itk is a Dual Action Regulator of Immunoreceptor Signaling in the Innate and Adaptive Immune System: A Dissertation
Jager The therapeutic effects of a suppressor of cytokine signaling 1 mimetic peptide in experimental allergic encephalomyelitis, a murine model of multiple sclerosis
Colombetti Dissecting the Molecular Mechanisms Regulating Proliferation, Antigen Responsiveness, and Differentiation of CD4+ T Lymphocytes: A Central Role for the Mammalian Target of Rapamycin (mTor)